Cardio3 BioSciences raises € 4.0 million in non-dilutive funding from the Walloon Region

Cardio3 BioSciences raises € 4.0 million in non-dilutive funding from the Walloon Region

Cardio3 BioSciences Partner and Exploitation Manager of a Eur 6.8 Million FP7 Research Grant for AMCARE Program

Cardio3 BioSciences Partner and Exploitation Manager of a Eur 6.8 Million FP7 Research Grant for AMCARE Program

Cardio3 BioSciences Partner and Exploitation Manager of a Eur 4.5 Million FP7 Research Grant

Cardio3 BioSciences Partner and Exploitation Manager of a Eur 4.5 Million FP7 Research Grant

Cardio3 Biosciences announces Q3 2013 business update and authorization to enroll patients in Poland in its chart-1 Phase III Clinical Trial

Cardio3 Biosciences announces Q3 2013 business update and authorization to enroll patients in Poland in its chart-1 Phase III Clinical Trial

Cardio3 Biosciences announces half year financial results and business update

Cardio3 Biosciences announces half year financial results and business update

Information on the total number of voting rights and shares

Information on the total number of voting rights and shares

Cardio3 BioSciences: Exercise of Over-allotment Option Total proceeds from the IPO €26.5m

Cardio3 BioSciences: Exercise of Over-allotment Option Total proceeds from the IPO €26.5m

Cardio3 BioSciences Raises EUR 23.0 million in Successful Initial Public Offering on NYSE Euronext Brussels and NYSE Euronext Paris

Cardio3 BioSciences Raises EUR 23.0 million in Successful Initial Public Offering on NYSE Euronext Brussels and NYSE Euronext Paris

Cardio3 BioSciences Launches its Initial Public Offering on NYSE Euronext Brussels and NYSE Euronext Paris

Cardio3 BioSciences Launches its Initial Public Offering on NYSE Euronext Brussels and NYSE Euronext Paris

PMV and SRIW Group Commit To Invest in Cardio3 BioSciences IPO

PMV and SRIW Group Commit To Invest in Cardio3 BioSciences IPO

Cardio3 BioSciences Announces Intention to Launch an Initial Public Offering on NYSE Euronext Brussels and NYSE Euronext Paris

Cardio3 BioSciences Announces Intention to Launch an Initial Public Offering on NYSE Euronext Brussels and NYSE Euronext Paris

Cardio3 BioSciences raises €19 million through a Private Placement

Cardio3 BioSciences raises €19 million through a Private Placement